PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
PD-L1
biomarkers
checkpoint inhibition
immune
immunotherapy
liquid biopsy
systemic myeloid subsets
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Aug 2020
18 Aug 2020
Historique:
received:
26
07
2020
revised:
11
08
2020
accepted:
13
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
17
2
2021
Statut:
epublish
Résumé
The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker with some prediction capabilities for the outcome of the treatment is PD-L1 expression in tumor biopsies. Nevertheless, even when having PD-L1-positive tumors, numerous patients do not respond to these treatments. Considering the high cost of these therapies and the risk of immune-related adverse events during therapy, it is necessary to identify additional biomarkers that would facilitate stratifying patients in potential responders and non-responders before the start of immunotherapies. Here, we review the utility of PD-L1 expression not only in tumor cells but in immune system cells and their influence on the antitumor activity of immune cell subsets.
Identifiants
pubmed: 32824655
pii: ijms21165918
doi: 10.3390/ijms21165918
pmc: PMC7460585
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundación Científica Asociación Española Contra el Cáncer
ID : PROYE16001ESCO
Organisme : Instituto de Salud Carlos III
ID : PI17/02119
Organisme : Departamento de Educación, Gobierno de Navarra
ID : BMED 050-2019
Organisme : Fundación Española para la Ciencia y la Tecnología
ID : Precipita
Organisme : Instituto de Salud Carlos III
ID : TRANSPOCART
Organisme : Departamento de Educación, Gobierno de Navarra
ID : DESCARTHES
Références
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
Nat Immunol. 2020 Apr;21(4):442-454
pubmed: 32152508
PLoS One. 2016 Oct 25;11(10):e0164514
pubmed: 27780254
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Onco Targets Ther. 2020 Feb 26;13:1757-1765
pubmed: 32161471
Leukemia. 2015 Jun;29(6):1441-4
pubmed: 25634684
Cancer J. 2018 Mar/Apr;24(2):70-77
pubmed: 29601333
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
J Surg Oncol. 2012 Sep 15;106(4):386-92
pubmed: 22422195
Science. 2015 Nov 20;350(6263):985-90
pubmed: 26494174
J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533
pubmed: 29951303
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
J Immunol. 2014 Oct 15;193(8):3835-41
pubmed: 25281753
J Clin Invest. 2017 Aug 1;127(8):3039-3051
pubmed: 28691930
Clin Cancer Res. 2016 Dec 1;22(23):5661-5672
pubmed: 27178742
J Clin Med. 2019 Mar 18;8(3):
pubmed: 30889786
World J Gastroenterol. 2012 Jul 7;18(25):3303-9
pubmed: 22783056
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
PLoS One. 2013 Aug 28;8(8):e72249
pubmed: 24015224
Cancer Med. 2018 Jun;7(6):2654-2664
pubmed: 29733528
Tumour Biol. 2014 Mar;35(3):2247-52
pubmed: 24136746
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Nat Cell Biol. 2014 Aug;16(8):717-27
pubmed: 25082194
Ann Surg Oncol. 2008 Jun;15(6):1775-82
pubmed: 18363071
Anticancer Res. 2019 Sep;39(9):5195-5201
pubmed: 31519633
Front Immunol. 2019 Feb 01;9:3101
pubmed: 30774636
Lung Cancer. 2018 Jun;120:108-112
pubmed: 29748004
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
Sci Immunol. 2017 Jul 28;2(13):
pubmed: 28754746
Transl Lung Cancer Res. 2018 Dec;7(6):682-690
pubmed: 30505713
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Bull Cancer. 2018 Nov;105(11):1033-1041
pubmed: 30244981
Int J Cancer. 2019 Nov 15;145(10):2611-2618
pubmed: 30989643
Transplant Proc. 2013 Jun;45(5):1853-5
pubmed: 23769057
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744168
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Cancer Res. 2018 Feb 15;78(4):845-852
pubmed: 29437766
Sci Transl Med. 2020 Mar 11;12(534):
pubmed: 32161104
Oncotarget. 2014 Sep 15;5(17):7843-57
pubmed: 25151659
Breast Cancer Res Treat. 2010 Aug;123(1):39-49
pubmed: 19898981
Allergol Int. 2017 Apr;66(2):326-331
pubmed: 27617656
Nat Commun. 2018 Jul 26;9(1):2921
pubmed: 30050132
J Immunol. 2007 Aug 1;179(3):1942-9
pubmed: 17641061
Cancer Immunol Res. 2016 Apr;4(4):345-53
pubmed: 26873574
Oncotarget. 2017 May 9;8(19):32171-32189
pubmed: 28418870
Clin Lung Cancer. 2019 Jul;20(4):270-277.e1
pubmed: 31005568
Sci Immunol. 2019 Jun 21;4(36):
pubmed: 31227596
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
Front Oncol. 2020 Jan 23;10:9
pubmed: 32038986
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Front Immunol. 2019 Jan 29;10:105
pubmed: 30761151
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Ann Oncol. 2019 Sep 1;30(9):1448-1459
pubmed: 31228184
Front Immunol. 2019 Feb 18;10:86
pubmed: 30833943
J Thorac Dis. 2018 Dec;10(12):6660-6669
pubmed: 30746211
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986912
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Clin Cancer Res. 2015 Jan 1;21(1):30-8
pubmed: 25564570
Int J Med Sci. 2017 Apr 8;14(5):403-411
pubmed: 28539815
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Oncoimmunology. 2016 Oct 20;5(12):e1247135
pubmed: 28123883
J Hematol Oncol. 2019 May 14;12(1):48
pubmed: 31088479
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31852845
Int J Cancer. 2015 May 15;136(10):2352-60
pubmed: 25353097
Int J Oncol. 2016 Dec;49(6):2206-2216
pubmed: 27779656
Front Immunol. 2018 Jan 17;8:2004
pubmed: 29387063
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Nat Rev Immunol. 2011 Jul 25;11(8):519-31
pubmed: 21785456
Clin Exp Immunol. 2010 Sep;161(3):471-9
pubmed: 20636398
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Acta Diabetol. 2018 May;55(5):515-517
pubmed: 29288375
J Oral Pathol Med. 2018 Nov;47(10):923-929
pubmed: 29961993
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Ecancermedicalscience. 2016 Dec 12;10:702
pubmed: 28105073
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Scand J Gastroenterol. 2017 Jan;52(1):93-99
pubmed: 27604386
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Immunobiology. 2017 Jan;222(1):82-88
pubmed: 26874580
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
Oncotarget. 2015 Dec 1;6(38):41228-36
pubmed: 26515600
Oncotarget. 2017 Nov 21;8(63):106171-106172
pubmed: 29290937
Sci Rep. 2016 Aug 24;6:31726
pubmed: 27553175
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Cancer. 2011 Jun 1;128(11):2663-72
pubmed: 20715106
Cell Death Dis. 2018 Mar 19;9(4):422
pubmed: 29556041
J Clin Med. 2019 Jul 09;8(7):
pubmed: 31323990
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
J Pathol Transl Med. 2019 Jul;53(4):199-206
pubmed: 31042863
Ann Oncol. 2018 Jan 1;29(1):193-199
pubmed: 29361135
Cancers (Basel). 2020 Feb 05;12(2):
pubmed: 32033266
J Cancer. 2019 Jun 2;10(11):2578-2587
pubmed: 31258764
Nat Immunol. 2020 Apr;21(4):365-366
pubmed: 32152507
J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101
pubmed: 30775032